Spondyloarthritis & psoriatic arthritis
Effect of bimekizumab on symptoms and impact of disease in patients with psoriatic arthritis over 3 years: results from BE ACTIVE
Authors' conclusion
Bimekizumab treatment was associated with long-term sustained improvements in pain and fatigue, reducing overall impact of PsA on patients. Physical function and quality of life improved up to 3 years.
Study context
- Population
- Patients with active PsA (mean age 49.3 years, 51.0% male)161 completed Week 152
- Participants
- 206 patients
Methodological details48-week randomised controlled trial, 104-week open-label extension, non-responder imputation for missing binary outcomes
- 48-week randomised controlled trial
- 104-week open-label extension
- Non-responder imputation for missing binary outcomes
Further findings
Fatigue (PsAID-9 fatigue), mean (S.E.M.) changes from baseline (CfB) · Week 48
- Mean (S.E.M.) CfB
- −2.4 (0.2)
Fatigue (PsAID-9 fatigue), mean (S.E.M.) CfB · Week 152
- Mean (S.E.M.) CfB
- −2.7 (0.2)
PsAID-9 patient-acceptable symptom state (PASS) (total score ≤4) · Week 48
- Patients achieving acceptable symptom state
- 75.2%
- Non-responder imputation
PsAID-9 PASS (total score ≤4) · Week 152
- Patients achieving acceptable symptom state
- 65.0%
- Non-responder imputation
Normal function (HAQ-Disability Index (HAQ-DI) <0.5) · Week 48
- Patients with normalised function
- 49.0%
- Non-responder imputation
Normal function (HAQ-DI <0.5) · Week 152
- Patients with normalised function
- 46.1%
- Non-responder imputation
PGA and SF-36 Physical Component Summary
- Improvements in PGA and SF-36 Physical Component Summary were also sustained
Original publication
Effect of bimekizumab on symptoms and impact of disease in patients with psoriatic arthritis over 3 years: results from BE ACTIVE. Rheumatology (Oxford). Published 5 July 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →